About: Everolimus     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz:8890 associated with source document(s)

AttributesValues
rdf:type
rdfs:label
  • Everolimus
rdfs:subClassOf
Concept_In_Subset
Semantic_Type
  • Pharmacologic Substance
Preferred_Name
  • Everolimus
NSC_Code
  • 733504
UMLS_CUI
  • C0541315
CAS_Registry
  • 159351-69-6
Accepted_Therapeutic_Use_For
  • with unresectable, locally advanced or metastatic neuroendocrine tumors of pancreatic origin
FDA_UNII_Code
  • 9HW64Q8G6G
Contributing_Source
  • FDA
ALT_DEFINITION
  • A drug used to treat advanced kidney cancer that did not respond to treatment with certain other anticancer drugs. It is also being studied in the treatment of other types of cancer. Afinitor stops cancer cells from dividing and may block the growth of new blood vessels that tumors need to grow. It also decreases the body's immune responses. It is a type of immunosuppressant and a type of antiangiogenesis agent.NCI-GLOSS
PDQ_Open_Trial_Search_ID
  • 372905
PDQ_Closed_Trial_Search_ID
  • 372905
Chemical_Formula
  • C53H83NO14
Legacy_Concept_Name
  • Everolimus
FULL_SYN
  • everolimusPTNCI-GLOSSCDR0000386203
  • (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaoneSNNCI
  • EverolimusPTDCP50567
  • RAD001PTNCI-GLOSSCDR0000639748
  • RAD 001CNNCI
  • EVEROLIMUSPTFDA9HW64Q8G6G
  • AfinitorPTNCI-GLOSSCDR0000639749
  • CerticanBRNCI
  • AfinitorBRNCI
  • 42-O-(2-Hydroxy)ethyl RapamycinSYNCI
  • EverolimusPTNCI
DEFINITION
  • A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)NCI
code
  • C48387
is someValuesFrom of
Faceted Search & Find service v1.16.121 as of Mar 31 2025


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3240 as of Mar 31 2025, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 14 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software